Lugano


LUGANO, Switzerland, December 7, 2011 - Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics Inc., has enrolled the first patient in ROMANA-3, the Company's 12-week safety extension study.

LUGANO, Switzerland and GREIFSWALD, Germany, September 27, 2011 - License Agreement for Germany on New Therapy in Development for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) Helsinn Healthcare SA, Switzerland and Riemser Arzneimittel AG, German licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing of a licensing agreement granting Riemser the commercialization rights for a next-generation treatment in development by Helsinn for the prevention of chemotherapy-induced nausea and vomiting (CINV) in Germany.

LUGANO, Switzerland, September 26, 2011 - The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated anorexia/cachexia, and netupitant + palonosetron oral fixed-dose combination in chemotherapy-induced nausea and vomiting (CINV) Helsinn, the Swiss pharmaceutical Group, global leader in the segment of the prevention of chemotherapy-induced nausea and vomiting (CINV) with the second generation 5-HT3 receptor antagonist palonosetron, is working very hard in reinforcing its cancer supportive care pipeline.

LUGANO, Switzerland, August 23, 2011 - Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer (NSCLC).
Older News
S M T W T F S
20 21 22 23 24 25 26
27 28 29 30 1 2 3
4 5 6 7 8 9 10
Copyright© 2011 The Gaea Times